金斯瑞(01548.HK)与镇江委员会订立投资协议 斥1.8亿人币投资建厂
金斯瑞生物科技(01548.HK)公布,与镇江委员会订立投资协议,镇江委员会将以零租金向金斯康香港提供合共20,000平方米的三间工厂,租期五年,连同於五年租期结束後按相同条件向金斯康香港提供收购或继续租赁该等工厂的优先权。
金斯康香港亦将透过其直接全资附属公司江苏金斯瑞生物科技将以固定资产及现金出资的形式投资总计1.8亿元人民币,用於建设工厂、办公大楼及其他仓储设施,以扩大分子生物产能、细胞治疗载体质粒技术的研究实验室,及多(月太)GMP业务。相关公司之注册资本将增加1,000万美元。其建设预计将於2020年上半年至2021年九月进行。
另外金斯康香港将获镇江委员会提供若干扶持政策,包括为工程及技术人员提供免租公寓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.